ELI LILLY & CO

25 December, 2024

Eli Lilly's Zepbound Outperforms Competitors, Elevating Company to Forefront of $100 Billion Weight Loss Drug Market

Eli Lilly continues to make headlines as a leader in the rapidly expanding obesity drug market. Recent trials have shown that its weight loss drug, Zepbound, outperforms Novo Nordisk's Wegovy, helping...
Read More

24 December, 2024

Eli Lilly Poised for Success in Obesity Market as Zepbound Outperforms Competitors Amidst Novo Nordisk Setbacks

Eli Lilly has recently strengthened its position in the competitive obesity drug market with its flagship treatment, Zepbound, demonstrating promising results. In the Surmount-1 study, Zepbound achiev...
Read More

23 December, 2024

Eli Lilly Sees Stock Surge as Rival Novo Nordisk Faces Setbacks in Obesity Drug Market

Eli Lilly's stock has witnessed a notable rise, fueled by disappointing results from rival Novo Nordisk's obesity drug, CagriSema. Following the negative update, Novo Nordisk experienced a nearly 20% ...
Read More

22 December, 2024

Eli Lilly's Zepbound Outperforms Competitors in Weight Loss Trials, Boosting Stock Amid Market Shift

Eli Lilly has emerged as a formidable player in the burgeoning obesity treatment market, particularly with its weight-loss drug, Zepbound, which recently outshone Novo Nordisk’s Wegovy in trials. Zepb...
Read More